[go: up one dir, main page]

TH133837A - - Google Patents

Info

Publication number
TH133837A
TH133837A TH1301000312A TH1301000312A TH133837A TH 133837 A TH133837 A TH 133837A TH 1301000312 A TH1301000312 A TH 1301000312A TH 1301000312 A TH1301000312 A TH 1301000312A TH 133837 A TH133837 A TH 133837A
Authority
TH
Thailand
Prior art keywords
ifn
conjugate
formula
peg
integer
Prior art date
Application number
TH1301000312A
Other languages
English (en)
Thai (th)
Original Assignee
นางดารานีย์ วัจนะวุฒิวงศ์ นางสาวสนธยา สังขพงศ์ นายณัฐพล อร่ามเมือง
Filing date
Publication date
Application filed by นางดารานีย์ วัจนะวุฒิวงศ์ นางสาวสนธยา สังขพงศ์ นายณัฐพล อร่ามเมือง filed Critical นางดารานีย์ วัจนะวุฒิวงศ์ นางสาวสนธยา สังขพงศ์ นายณัฐพล อร่ามเมือง
Publication of TH133837A publication Critical patent/TH133837A/th

Links

TH1301000312A 2010-09-24 TH133837A (uk)

Publications (1)

Publication Number Publication Date
TH133837A true TH133837A (uk) 2014-05-19

Family

ID=

Similar Documents

Publication Publication Date Title
Gurunathan et al. Antiviral potential of nanoparticles—can nanoparticles fight against coronaviruses?
PH12012502425A1 (en) The new stable polyethylene glycol conjugate of interferon alpha, represented by one positional isomer
EP2433622B1 (en) Agent for the prophylaxis and treatment of highly pathogenic infectious diseases
Yang et al. Nanotechnology advances in pathogen-and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control
JP2009535352A5 (uk)
EA201171376A1 (ru) Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса
Ramezankhani et al. Therapeutic modalities and novel approaches in regenerative medicine for COVID-19
EA037430B1 (ru) Противовирусное иммунотропное средство для лечения орви
Haddad et al. A comprehensive review on the efficacy of several pharmacologic agents for the treatment of COVID-19
Chopra et al. Liposomes as nanocarriers for anti-HIV therapy
Ashaolu et al. Potential “biopeptidal” therapeutics for severe respiratory syndrome coronaviruses: a review of antiviral peptides, viral mechanisms, and prospective needs
EA201101035A1 (ru) Новый конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем
Koudstaal et al. Pre-and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir
Tarbet et al. A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses
Redman et al. Pharmacokinetic and chemical synthesis optimization of a potent D-peptide HIV entry inhibitor suitable for extended-release delivery
Chen et al. Antiviral nanoagents: More attention and effort needed?
de M Ribeiro et al. The role of pharmaceutical nanotechnology in the time of COVID-19 pandemic
Durán et al. Nanobiotechnology solutions against Aedes aegypti
RU2448692C2 (ru) Фармацевтические соли аминобицикло[2.2.1]гептанов как ингибиторы транскрипционного фактора nf-kb с противовирусной активностью (варианты) и их применение
Aderibigbe Polymeric therapeutic delivery systems for the treatment of infectious diseases
Shankaran et al. Treatment of severe cases of pandemic (H1N1) 2009 influenza: review of antivirals and adjuvant therapy
TH133837A (uk)
AMOL et al. Role of Rasayan churna in outbreak of COVID-19 as preventive and curative aspect
AU2005244826B2 (en) Treatment or prevention of respiratory viral infections with immunomodulator compounds
US11724077B2 (en) Therapeutic swabs for treating upper respiratory infections